|
|||||
|
|||||
|
|
|
|
|
|
|
|||||
 |
 |
    |
|
|
|||
 |
|
||
|
|||
|
|
|
|
||||||||
|
U.S. Response II: Biological Defense Projects Divert Funds From Other Medical Research, Experts Say Experts have said that the Bush administration’s plans for increased biological defense research could take away necessary funding from other medical research projects, BBC News reported yesterday. For example, the U.S. National Institute of Allergy and Infectious Diseases plans to spend $145 million to purchase and test a new experimental anthrax vaccine (see GSN, July 10). Half of that funding, however, will be taken from research projects on other diseases, such as AIDS, under White House orders due to a lack of congressional funding, according to BBC News. Luis Montaner of the Wistar Institute said he had just begun an AIDS research project when his funding was cut. “This basically means for our own research that we have to scale back, to readdress our aims and perhaps accomplish less than what we would have hoped we could accomplish,” Montaner said. “If there is a commitment that bioterrorism needs to be met by a comprehensive scientific agenda which includes, for example, anthrax vaccines, that should not be at the expense of other, equally important research programs,” he said (Richard Black, BBC News, July 10).
| ||||||||||
Back to top
